Company: WHWK
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001628280-25-015269
Chunk: 5

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 8
Chunk 5
---
 78 Proceeds from issuance under employee stock purchase plan146 408 Deferred offering costs paid for financing(16)(160)Net cash provided by financing activities130 326 Net (decrease) increase in cash, cash equivalents and restricted cash(34,218)23,869 Cash, cash equivalents and restricted cash at beginning of year62,952 39,083 Cash, cash equivalents and restricted cash at end of year$28,734 $62,952 

The accompanying notes are an integral part of these consolidated financial statements.

120

WHITEHAWK THERAPEUTICS, INC.

Consolidated Statements of Cash Flows (continued)

(in thousands)

Year Ended December 31,20242023Supplemental disclosure of cash flow information:Interest paid during the period$211 $230 Supplemental disclosure of non-cash activities:Deferred transaction costs included in accounts payable and accrued liabilities$35 $46 Amounts accrued for purchases of property and equipment$1,153 $571 

The accompanying notes are an integral part of these consolidated financial statements.

121